Company Overview - Daxor Corporation is a leader in blood volume measurement technology, addressing the critical issue of accurately measuring blood volume in healthcare, which is linked to prolonged hospital stays and increased readmissions for conditions like heart failure [5] - The company has developed a portable blood volume analyzer that provides rapid, lab-quality results, making Blood Volume Analysis (BVA) easier to implement in various clinical settings [2][3] Product Impact - Daxor's BVA has shown significant improvements in patient outcomes, altering fluid and red blood cell interventions in 44% of cases and reducing mortality by 66% in surgical intensive care units [3] - The new analyzer is expected to help hospitals reduce costs associated with the over five million annual adult ICU admissions in the U.S., which exceed $100 billion in annual healthcare spending [2][3] Market Position and Strategy - Daxor aims to reshape patient care and improve healthcare economics by reducing ventilator days and hospital length of stay through its innovative technology [3] - The company operates a state-of-the-art manufacturing facility in the U.S. and is positioned for accelerated market expansion, supported by 50 years of experience and innovation [5]

Financial Data and Key Metrics Changes - As of December 31, 2024, Daxor's net assets increased to $36.79 million or $7.25 per share, up from $34.01 million or $7.08 per share at the end of 2023, reflecting a positive trend in net asset value [7] - For the year ended December 31, 2024, Daxor reported net dividend income of $0.10 million and net realized gains on investment securities of $1.36 million, while there was a net decrease in unrealized appreciation of $1.15 million due to the sale of positions [8] - The net increase in net assets from operations was $0.55 million, which included a non-cash stock-based compensation expense of $1.25 million [9] Business Line Data and Key Metrics Changes - Revenue in the operating company increased by 116.5% year-on-year from 2024 compared to 2023, indicating strong growth momentum [29] - The number of diagnostic kits sold rose by 60.1% year-on-year for 2023, following a growth of about 37% in the prior year [30] - The operating company achieved cash flow breakeven in the first quarter of 2025, excluding costs related to stock-based compensation, depreciation, and amortization [29] Market Data and Key Metrics Changes - Daxor signed 12 new accounts in 2024, including five that purchased analyzer systems, with three additional accounts signed in the first two months of 2025 [31] - The company received a $2.5 million contract from the U.S. Department of Defense, which will pay out monthly over a two-year duration [32] - Additional funding awards from the National Institutes of Health and other sources totaled more than $350,000 in the second half of 2024 [33] Company Strategy and Development Direction - Daxor aims to commercialize products for optimal patient care around blood volume management, focusing on improving outcomes for millions of patients [23] - The company is pursuing the development of next-generation blood volume analyzers, which are expected to significantly enhance speed, access, and accuracy in fluid management [44] - Daxor plans to bring manufacturing of diagnostic kits in-house, which is expected to increase margins and improve cash flow [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting substantial progress in revenue growth, customer acquisition, and product utilization [22] - The management team emphasized the importance of real-world data generation and peer-reviewed publications to facilitate practice change in clinical settings [16] - The company anticipates that the transition to a more transparent reporting structure will positively impact its valuation and market potential [52] Other Important Information - Daxor is classified as a closed-end management company under the Investment Company Act of 1940, with plans to secure a designation as an operating company by the end of 2025 [51] - The company has developed strong relationships with various healthcare providers, expanding its market reach beyond traditional cardiology [15] Q&A Session Summary Question: Can you discuss the cash transfer to the operating company? - The company transferred $1.6 million to the operating company to cover capital expenditures, inventory build, and R&D, with the operating company achieving cash flow positivity in early 2025 [54][55] Question: What are the efforts to build the sales team? - The company is actively building its commercial teams through internal hires and potential distributor agreements, realizing substantial value from its unique technology [56] Question: Can you elaborate on the competitive landscape? - The competitive landscape is focused on indirect proxy measures, while Daxor has pioneered a more accurate method for directly measuring blood volume, providing a significant competitive advantage [58][59]